Parkinson disease (PD) is characterized by the loss of midbrain dopaminergic neurons as well as other brainstem neurons [1, 2]. Loss of pontine neurons may result in non-motor features of PD such as mood and sleep impairments and/or may be relevant to motor disability [3]. Routine MRI methods were shown to be insensitive to detect pontine changes in PD, but MRI voxel-based morphometry and diffusion tensor imaging have recently detected brainstem changes in PD [4] and REM sleep disorder (RBD) [5]. We have developed adiabatic MRI methods (R 1ρ and R 2ρ ) that detect midbrain changes in PD [6,7] and are useful in assessing the aphakia mouse model lacking dopaminergic neurons in substantia nigra of the brain [8]. Another method that we have recently developed attempts to address poor MRI sensitivity that has been observed using qualitative magnetization transfer ratios (MTRs). Our modified acquisition and data analysis protocols provide robust estimate of R 1 in the presence of off-resonance saturation (R 1sat ). This approach allows reliable quantification of the magnetization transfer (MT) effect [9], often used as a maker of tissue integrity. In this study, we aimed at investigating the ability of adiabatic R 1ρ and R 1sat to detect changes in the brainstem of PD patients as compared to agematched control subjects.
Introduction
Parkinson disease (PD) is characterized by the loss of midbrain dopaminergic neurons as well as other brainstem neurons [1, 2] . Loss of pontine neurons may result in non-motor features of PD such as mood and sleep impairments and/or may be relevant to motor disability [3] . Routine MRI methods were shown to be insensitive to detect pontine changes in PD, but MRI voxel-based morphometry and diffusion tensor imaging have recently detected brainstem changes in PD [4] and REM sleep disorder (RBD) [5] . We have developed adiabatic MRI methods (R 1ρ and R 2ρ ) that detect midbrain changes in PD [6, 7] and are useful in assessing the aphakia mouse model lacking dopaminergic neurons in substantia nigra of the brain [8] . Another method that we have recently developed attempts to address poor MRI sensitivity that has been observed using qualitative magnetization transfer ratios (MTRs). Our modified acquisition and data analysis protocols provide robust estimate of R 1 in the presence of off-resonance saturation (R 1sat ). This approach allows reliable quantification of the magnetization transfer (MT) effect [9] , often used as a maker of tissue integrity. In this study, we aimed at investigating the ability of adiabatic R 1ρ and R 1sat to detect changes in the brainstem of PD patients as compared to agematched control subjects.
Methods
The brains of nine non-demented individuals with mild-moderate PD (59 ± 9 years old, mean ± SD) and ten age-matched healthy volunteers (57 ± 9 years old) were imaged at 4T. Patients with PD were off their usual antiparkinsonian medications for 12 hours prior to imaging. Images were acquired using fast spin echo readout, TR = 6.5-10 s, TE = 0.073 s, matrix 256 x 256, FOV = 25.6 cm x 25.6 cm, and slice-thickness = 4mm. In the adiabatic R 1ρ configuration, a train of 0, 4, 8, 12 and 16 hyperbolic secant pulses was placed prior to the imaging readout. RF peak amplitude ω 1 max /(2π) of the adiabatic pulses was 0.88 kHz, pulse duration was 0.006 s, and the inversion bandwidth was ~1.6 kHz. For the MT experiment, a 6 kHz off-resonance continuous-wave pulse, with incremental duration (0, 0.2, 0.5, 0.8, 1.0, 1.2 s) and pulse amplitude of ω 1 max /(2π) = 0.15 kHz, was placed prior to the imaging readout with or without initial global inversion [9] . Differences of relaxation rates (ΔR 1ρ and ΔR 1sat ) were calculated between various sub-regions of the brainstem in each subject, and were then compared between patients and controls with two-tailed unpaired student t-test.
Results and Discussion
Representative R 1ρ and R 1sat maps from control (top) and PD (bottom) subjects are shown in figure. The analyzed regions of interest are indicated on the T 2 -weighted images. Statistically significant different ΔR 1ρ were observed when comparing ROI-1 vs ROI-5 and ROI-1 vs ROI-6 between patients and control subjects (p=0.004 and p=0.033, respectively). ΔR 1ρ were 6 and 8 times larger in patients than in controls for ROI-1 vs ROI-5 and ROI-1 vs ROI-6, respectively. Notably, R 1ρ values in ROI-1 were not different between patients and controls (p=0.25), whereas faster R 1ρ values were observed in ROI-5 and ROI-6 of PD as compared to controls, with p-values close to significance level (p=0.062 and p=0.077, respectively). Based on these observations, the changes in R 1ρ between PD and controls primarily arose from the medullary nuclei rather than the more rostral regions. Finally, no statistical differences were observed between patients and controls when considering R 1sat , indicating no changes in tissue integrity. This is again supported by the absence of slower R 1ρ values in those regions. Together, our findings of faster R 1ρ values and no R 1sat changes in the medullary nuclei might indicate changes in the macromolecular composition which occur prior to neuronal death within the same structures. Braak et al. have emphasized medullary and pontine pathology in addition to classic midbrain involvement in PD [1] , hypothesizing that the disease progresses from caudal to more rostral brain regions. Medullary and pontine pathology includes formation of Lewy bodies and neurites, and subsequent neuronal loss in the brainstem structures such as the raphe nucleus, locus ceruleus and lateral tegmental nuclei [2, 3, 10] . Our imaging study showed differences in MR parameters in the medullary regions of the brainstem of mild-moderately affected individuals that may be due to structural changes from the disease. Since a relatively small number of patients were enrolled, we were not able to determine if imaging findings correlated with disease severity or a clinical feature such as depression or RBD. Nevertheless, the results showed MRI changes in PD which are consistent with both clinical and pathological understating of the disease.
